Canada · Delayed Price · Currency is CAD Covalon Technologies Earnings Call Transcripts
Fiscal Year 2026
-
Q3 saw 20% revenue growth and record profitability, driven by U.S. vascular access and contamination protection solutions. Gross margin exceeded 67%, net income surged, and cash flow enabled both a dividend and capital investment. Management remains optimistic for continued growth.
-
Q2 delivered strong revenue and margin growth, with adjusted EBITDA more than doubling year-over-year. Adoption of contamination prevention products is accelerating at leading hospitals, and management expects a robust second half with continued operating leverage.
-
Q1 revenue declined year-over-year, but gross margins remained strong and Q2 is already outperforming Q1. Major new hospital wins, strong customer retention, and investments in automation and IT are driving optimism for robust growth in fiscal 2026.
Fiscal Year 2025
-
Achieved record Q4 revenue and 5% annual growth, driven by strong U.S. and international sales, despite a decline in advanced wound care due to inventory and partner issues. Maintained high gross margins, paid a special dividend, and ended the year with strong cash and no debt.
-
The company is focused on wound care and vascular access, leveraging unique products and clinical evidence to drive growth, especially in the U.S. Recent financial strength enabled a special dividend, while ongoing investments and strategic flexibility position it for future expansion.
-
Q3 saw over 10% sequential revenue growth, strong U.S. and international expansion, and robust cash generation. Adjusted gross margin improved after one-time charges, and management expects continued growth and margin stabilization into Q4 and next year.
-
Revenue and profitability remain strong, with double-digit growth in key segments and a robust cash position. Gross margin dipped due to higher international sales but is expected to rebound as U.S. sales accelerate. Strategic focus on market development, M&A, and clinical evidence supports a positive outlook.
-
Q1 saw 75% year-over-year revenue growth, positive net income, and strong cash generation, with key wins in U.S. hospital markets and new product approvals. Sequential revenue dipped due to inventory normalization, but growth is expected to accelerate in the second half of fiscal 2025.
Fiscal Year 2024
-
Delivered strong Q4 and FY2024 results with 17% revenue growth and a major turnaround to positive net income and EBITDA, driven by U.S. medical consumables. Cash nearly doubled to $16.7M, with a focus on operational efficiency and multi-year growth opportunities.
-
Focused on infection prevention and wound care, the company has achieved strong U.S. growth, improved margins, and a turnaround to profitability. Operational changes, product innovation, and customer retention drive future expansion, supported by a robust cash position.
-
Q3 saw revenue rise 47% year-over-year to CAD 9.2 million, with adjusted EBITDA of CAD 2.4 million and EPS of CAD 0.06. U.S. product growth and cost control drove profitability, while international revenue was flat. Management remains optimistic about long-term growth.